168. Ehlers-Danlos syndrome Clinical trials / Disease details
Clinical trials : 8 / Drugs : 17 - (DrugBank : 9) / Drug target genes : 9 - Drug target pathways : 55
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04890431 (ClinicalTrials.gov) | June 2021 | 6/5/2021 | Impact of Oxygen Therapy on Fatigue in Patients With Hypermobile-type Ehlers-Danlos Syndrome | Impact of Oxygen Therapy on Fatigue in Patients With Hypermobile-type Ehlers-Danlos Syndrome: a Randomised Double-blind Placebo-controlled Study | Ehlers-Danlos Syndrome | Drug: Oxygen;Drug: Placebo | Hospital St. Joseph, Marseille, France | NULL | Not yet recruiting | 18 Years | N/A | All | 82 | Phase 4 | NULL |
| 2 | NCT02597361 (ClinicalTrials.gov) | January 2016 | 23/10/2015 | Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE) | Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome: a Double Blind, Randomized, Placebo Controlled, Multicenter Trial. | Ehlers-Danlos Syndrome, Vascular Type | Drug: Irbesartan;Drug: Placebo | Assistance Publique - Hôpitaux de Paris | Ministry of Health, France | Completed | 18 Years | 70 Years | All | 61 | Phase 3 | France |
| 3 | NCT00190411 (ClinicalTrials.gov) | October 2003 | 13/9/2005 | Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type | Prevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos Syndrome | EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT;CHROMOSOME 2q31.2 DELETION SYNDROME | Drug: celiprolol;Drug: Control | Assistance Publique - Hôpitaux de Paris | Aventis Pharmaceuticals | Completed | 15 Years | 65 Years | Both | 54 | Phase 4 | France |